AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02972645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC
Study NCT02972645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03218865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIE high flux dialyzer
Description: Asssesment of the therapeutic effect of the vitamin E coating
Study NCT03218865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leoceed H high flux dialyzer
Description: Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
Study NCT02458235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
Study NCT02458235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
Study NCT00895921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Single intramuscular 10-mg dose
Study NCT02425254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: 1000mg intravenous solution for infusion
Study NCT00895921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Single intramuscular 9.75-mg dose
Study NCT02437318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT02437318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Study NCT02437318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Study NCT02437318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib placebo
Study NCT02001168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
Study NCT02001168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
Study NCT02001168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh-Endostatin
Description: rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
Study NCT02425254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Description: 1000mg intravenous solution for infusion
Study NCT02425254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous saline 0.9%
Description: 0.9% sodium chloride in order to ensure double-blinding
Study NCT02425254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline 0.9%
Description: 0.9% sodium chloride in order to ensure double-blinding
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDEPA
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDEPA
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
Study NCT02399631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery program
Description: Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
Study NCT03143387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries removal using only manual instruments
Description: Caries removal using only manual instruments according to Atraumatic Restorative Treatment
Study NCT03143387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caries removal using Papacarie gel
Description: Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
Study NCT03309917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 80-85 mmHg for 5 min
Description: MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
Study NCT03309917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 70-75 mmHg for 5 min
Description: MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
Study NCT03309917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 60-65 mmHg for 5 min
Description: MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
Study NCT01162278 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: Single fraction SBRT
Study NCT01514825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT04135209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography OCTA
Description: Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
Study NCT04716166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-oriented incentive spirometry
Description: 3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
Study NCT01691872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Retigabine
Study NCT03478319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-2494 or placebo
Description: Recombination fusion protein
Study NCT00786448 — intervention group
Intervention type: DRUG
Intervention: Darifenacin, Emselex (BAY79-4998)
Description: Patients from routine practice
Study NCT02001168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Description: Cis-platinum 60mg/m2, d1, 21 d as a cycle.
Study NCT01202695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-21D9
Description: intravenously, single dose
Study NCT01202695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04542928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse facilitated face care group
Description: The experimental group is required to receive a nurse leading 50- minute face care group every two week
Study NCT04542928 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nurse facilitated face care group
Description: The experimental group is required to receive a nurse leading 50- minute face care group every two week
Study NCT03888755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Participants will receive icatibant 30 mg SC injection in the abdominal area.
Study NCT00982033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren
Description: aliskiren 300mg qd versus placebo for 24 weeks.
Study NCT03650452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 tablets or mini-tablets.
Study NCT03650452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching tablets or mini-tablets.
Study NCT02969317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed dose combination
Study NCT02969317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed dose combination
Study NCT04573452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Galectin-3
Description: Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
Study NCT04573452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Placental Galactin-3
Description: Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Study NCT02728258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT02728258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02678741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLPLDC Vaccine
Description: Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
Study NCT00982033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd for 24 weeks
Study NCT02119884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
Study NCT02119884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
Study NCT06054022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
Study NCT06054022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasoprong oxyen 2Litres per minute
Description: nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
Study NCT04892758 — intervention group
Intervention type: DRUG
Intervention: Formoterol fumarate 10 mcg
Description: Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
Study NCT03677999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
Description: MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
Study NCT01514825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00852917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.
Study NCT04892758 — intervention group
Intervention type: DRUG
Intervention: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Description: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
Study NCT03503682 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03503682 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study NCT01503060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational video - Active
Description: The active video will instruct parents in techniques related to optimal infant soothing.
Study NCT00852917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet daily.
Study NCT02412462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-16B5
Study NCT01503060 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational Video - Sham
Description: The sham video will provide general information about immunization immunization pain management.
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose Placebo (water)
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose Placebo (water)
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
Study NCT02504814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF)
Description: changes in breathing physiology in NHF
Study NCT01610063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic algorithm
Description: Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Placebo
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Placebo
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study NCT01503060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study NCT01111539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.
Study NCT01111539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.
Study NCT01111539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.
Study NCT03539458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement
Study NCT02738437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite-bone cement
Study NCT01333267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone-related Protein (1-36)
Description: PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
Study NCT01333267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parathyroid hormone (1-34)
Description: PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
Study NCT01333267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) and PTHrP (1-36)
Description: This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
Study NCT03537820 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire EVAN-G
Study NCT01826422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA
Description: Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
Study NCT01826422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
Study NCT03443726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block technique
Description: Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
Study NCT03443726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltrative technique
Description: Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
Study NCT03443726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% articaine 1:100.000 epinephrine
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
Study NCT03443726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% articaine 1:100.000 epinephrine
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
Study NCT03443726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar extraction
Description: Third molar extraction under local anesthesia.
Study NCT03443726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Third molar extraction under local anesthesia.
Study NCT01536977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01536977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01536977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo BBT-I
Study NCT01536977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Ancillary studies
Study NCT01536977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo BBT-I
Study NCT04760119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein bypass surgery first strategy
Description: Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
Study NCT04760119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment first (drug coated balloon angioplasty) strategy
Description: Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
Study NCT01830010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 1: KRP203
Description: All subjects will receive KRP203 for 111 days
Study NCT01830010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 2: KRP203 lower dose
Study NCT01830010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 2: KRP203 higher dose
Study NCT02001714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Treatment
Description: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
Study NCT02209740 — intervention group
Intervention type: OTHER
Intervention: Tenofovir switch
Description: Patients switched tenofovir to different antiretroviral regimen according to physicians decision
Study NCT04089488 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Correlative studies
Study NCT04089488 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Respond to surveys
Study NCT01818778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program
Description: The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
Study NCT01818778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Friendly Visit
Description: Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident.
Study NCT00890500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m2/day IV x 6 days